Thu, February 13, 2025
Wed, February 12, 2025
Tue, February 11, 2025
[ Tue, Feb 11th ] - Forbes
LLC Tax Changes In 2025
Mon, February 10, 2025
Sun, February 9, 2025
Sat, February 8, 2025
[ Sat, Feb 08th ] - techUK
AI Action Summit: Day 1
Fri, February 7, 2025
[ Fri, Feb 07th ] - Indiatimes
RBI MPC Meeting Live
Thu, February 6, 2025

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say


//science-technology.news-articles.net/content/2 .. buy-us-biotech-firm-springworks-sources-say.html
Published in Science and Technology on Monday, February 10th 2025 at 12:22 GMT by MSN   Print publication without navigation

  • Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.

Merck KGaA, a German science and technology company, is currently in discussions to acquire SpringWorks Therapeutics, a U.S.-based biotech firm, according to sources familiar with the matter. SpringWorks Therapeutics specializes in developing treatments for severe rare diseases and cancer, with its lead candidate, nirogacestat, recently receiving FDA approval for treating desmoid tumors. The potential acquisition could enhance Merck's portfolio in oncology and rare diseases, aligning with its strategic focus on expanding its healthcare business. However, details such as the deal's value and structure remain undisclosed, and there's no confirmation yet on whether an agreement will be reached.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/general/exclusive-germany-s-merck-kgaa-in-talks-to-buy-us-biotech-firm-springworks-sources-say/ar-AA1yLgI5 ]

Publication Contributing Sources